Indaptus Therapeutics
INDP
6 hedge funds and large institutions have $10.2M invested in Indaptus Therapeutics in 2016 Q1 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
24% less capital invested
Capital invested by funds: $13.4M → $10.2M (-$3.22M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$186K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$37.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$344K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $3.3M | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $2.95M | +$186K | +20 | +7% |
|
|
OM
3
Opaleye Management
Boston,
Massachusetts
| $2.63M | +$37.2K | +4 | +1% |
|
|
PA
4
Perceptive Advisors
New York
| $795K | -$344K | -37 | -30% |
|
|
DCM
5
DAFNA Capital Management
Los Angeles,
California
| $491K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $12K | -$9.31K | -1 | -50% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
INDP Hedge Fund Activity: Q1 2016 in Review
6 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2016, worth a combined $10.2M — down 24% from $13.4M a quarter earlier.
Fund positioning in INDP was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, adding an estimated $186K. The largest seller was Perceptive Advisors, cutting an estimated $344K.
- 6 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $10.2M of Indaptus Therapeutics stock for Q1 2016, down 24% quarter-over-quarter.
- 0 funds opened new Indaptus Therapeutics positions in Q1 2016 and 0 closed out.
- The largest Indaptus Therapeutics buyer in Q1 2016 was Sabby Management, an estimated $186K added.
- The largest Indaptus Therapeutics seller in Q1 2016 was Perceptive Advisors, an estimated $344K sold.
Based on aggregated 13F filings for Q1 2016.